Acurx Pharmaceuticals, Inc.: 10-Q filed 2023-05-12
What Acurx Pharmaceuticals, Inc. reported in its quarterly report filed 2023-05-12 (fiscal Q1 2023): 19 published measures, 42 facts as tagged in accession 0001558370-23-009495.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2023-05-12
- Fiscal period
- fiscal Q1 2023
- Accession
- 0001558370-23-009495 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Acurx Pharmaceuticals, Inc. filings.
Reported measures
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-03-31 | 2,073,982 | USD | |
| At 2022-12-31 | 2,061,685 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-03-31 | 5,311,439 | USD | |
| At 2022-12-31 | 7,315,021 | USD | |
| At 2022-03-31 | 10,689,272 | USD | |
| At 2021-12-31 | 12,410,241 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-01-01 to 2023-03-31 | -2,902,957 | USD | 90 |
| 2022-01-01 to 2022-03-31 | -2,670,138 | USD | 90 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-01-01 to 2023-03-31 | -1,932,931 | USD | 90 |
| 2022-01-01 to 2022-03-31 | -1,876,000 | USD | 90 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-03-31 | -41,544,042 | USD | |
| At 2022-12-31 | -38,641,085 | USD |
Basic weighted-average shares
Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-01-01 to 2023-03-31 | 11,639,395 | shares | 90 |
| 2022-01-01 to 2022-03-31 | 10,232,843 | shares | 90 |
Diluted weighted-average shares
Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-01-01 to 2023-03-31 | 11,639,395 | shares | 90 |
| 2022-01-01 to 2022-03-31 | 10,232,843 | shares | 90 |
Basic earnings per share
Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-01-01 to 2023-03-31 | -0.25 | USD/shares | 90 |
| 2022-01-01 to 2022-03-31 | -0.26 | USD/shares | 90 |
Diluted earnings per share
Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-01-01 to 2023-03-31 | -0.25 | USD/shares | 90 |
| 2022-01-01 to 2022-03-31 | -0.26 | USD/shares | 90 |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-01-01 to 2023-03-31 | 733,472 | USD | 90 |
| 2022-01-01 to 2022-03-31 | 761,069 | USD | 90 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-03-31 | 7,385,421 | USD | |
| At 2022-12-31 | 9,376,706 | USD |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-03-31 | 2,073,982 | USD | |
| At 2022-12-31 | 2,061,685 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-01-01 to 2023-03-31 | 2,902,957 | USD | 90 |
| 2022-01-01 to 2022-03-31 | 2,670,138 | USD | 90 |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-01-01 to 2023-03-31 | 1,015,583 | USD | 90 |
| 2022-01-01 to 2022-03-31 | 818,888 | USD | 90 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-03-31 | 11,671,795 | shares | |
| At 2022-12-31 | 11,627,609 | shares |
Cash including restricted cash
Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-03-31 | 7,178,820 | USD | |
| At 2022-12-31 | 9,111,751 | USD | |
| At 2022-03-31 | 11,082,846 | USD | |
| At 2021-12-31 | 12,958,846 | USD |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2023-03-31 | 46,843,809 | USD | |
| At 2022-12-31 | 45,944,478 | USD |
Profit or loss including noncontrolling interests
Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-01-01 to 2023-03-31 | -2,902,957 | USD | 90 |
| 2022-01-01 to 2022-03-31 | -2,670,138 | USD | 90 |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2023-01-01 to 2023-03-31 | 1,887,374 | USD | 90 |
| 2022-01-01 to 2022-03-31 | 1,851,250 | USD | 90 |
Inspect the source
- Entity
- Acurx Pharmaceuticals, Inc. / CIK 0001736243
- Captured
- 2026-09-21T17:25:29.911Z
- SEC response SHA-256
3ff72a27b12e3bbf2238c568e6d540d3ffd8acf36c9060b3da0911bb5446b5e9
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001736243.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))